Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of CAI is 40 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell